Perigon Wealth Management LLC Boosts Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Perigon Wealth Management LLC raised its position in AstraZeneca PLC (NASDAQ:AZN) by 3.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,597 shares of the company’s stock after purchasing an additional 567 shares during the period. Perigon Wealth Management LLC’s holdings in AstraZeneca were worth $1,311,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. AQR Capital Management LLC lifted its stake in shares of AstraZeneca by 112.4% during the second quarter. AQR Capital Management LLC now owns 13,685 shares of the company’s stock valued at $1,067,000 after buying an additional 7,241 shares during the period. The Manufacturers Life Insurance Company raised its holdings in AstraZeneca by 39.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 206,446 shares of the company’s stock valued at $16,104,000 after acquiring an additional 58,039 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of AstraZeneca by 13.2% during the second quarter. NewEdge Advisors LLC now owns 49,589 shares of the company’s stock worth $3,867,000 after purchasing an additional 5,779 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of AstraZeneca by 2.1% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 86,163 shares of the company’s stock worth $6,720,000 after purchasing an additional 1,737 shares during the last quarter. Finally, Truist Financial Corp increased its stake in AstraZeneca by 4.6% in the second quarter. Truist Financial Corp now owns 250,478 shares of the company’s stock valued at $19,535,000 after purchasing an additional 11,074 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AZN has been the topic of a number of research analyst reports. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Up 1.4 %

AZN opened at $71.24 on Friday. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The firm has a 50 day moving average price of $66.83 and a 200 day moving average price of $73.99. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The company has a market cap of $220.92 billion, a PE ratio of 34.09, a price-to-earnings-growth ratio of 1.13 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.87 earnings per share. Sell-side analysts expect that AstraZeneca PLC will post 4.12 earnings per share for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.